Loading
ST
SOC Telemed, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Alyeska Investment Group, L.P., was filed 02 Nov 2020.
SOC Telemed, Inc.: what insiders have been doing
Every trade that managers of SOC Telemed, Inc. disclose to SEC (Form 4) is tracked on this page. The company sits in the Healthcare & Pharma sector. The past year has been quiet: not a single insider filing for SOC Telemed, Inc. The previous disclosure was published on 7 April 2022.
Over the whole record (from 2019), the tally stands at 30 purchases and 2 sales.
Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
81
Thresholds
n/a
Buy Volume
€28M
30 ops. · all time
Sell Volume
€371,926
2 ops. · all time
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2021FY ended December 2021 · cache
Income statement
RevenueUS$81.3M
Net income-US$43.5M-53.5% margin
Last declaration on 7 April 2022
Declarations81 total
401,243 sharesClass A Common StockSEC:0001209191-22-023663:1
101,325 shares@ US$3.00100.0% of flowClass A Common StockSEC:0001209191-22-023674:0
15,677 shares@ US$3.0071.2% of flowClass A Common StockSEC:0001209191-22-023668:0
496,576 shares@ US$3.00100.0% of flowClass A Common StockSEC:0001209191-22-023676:0
44,150 shares@ US$3.00100.0% of flowClass A Common StockSEC:0001209191-22-023659:0
58,387 shares@ US$3.00100.0% of flowClass A Common StockSEC:0001209191-22-023657:0
1,112,291 shares@ US$3.00100.0% of flowClass A Common StockSEC:0001209191-22-023679:0
22,168 shares@ US$3.00100.0% of flowClass A Common StockSEC:0001209191-22-023671:0
58,387 shares@ US$3.00100.0% of flowClass A Common StockSEC:0001209191-22-023675:0
79,185 shares@ US$3.00100.0% of flowClass A Common StockSEC:0001209191-22-023667:0
90,591 shares@ US$3.00100.0% of flowClass A Common StockSEC:0001209191-22-023658:0
3,316,679 sharesClass A Common StockSEC:0001209191-22-023663:0
33,874,965 shares@ US$3.00100.0% of flowClass A Common StockSEC:0001213900-22-018700:0
6,491 shares@ US$2.984228.8% of flowClass A Common StockSEC:0001209191-22-022355:0
450,000 shares0Class A Common StockSEC:0001209191-21-070991:0
1,080,000 shares0Class A Common StockSEC:0001209191-21-070992:0
4,915 shares0Class A Common StockSEC:0001209191-21-038689:1
5,618 shares0Class A Common StockSEC:0001209191-21-038700:1
21,067 shares0Class A Common StockSEC:0001209191-21-038700:0
21,067 shares0Class A Common StockSEC:0001209191-21-038689:0
21,067 shares0Class A Common StockSEC:0001209191-21-038683:0
21,067 shares0Class A Common StockSEC:0001209191-21-038693:0
21,067 shares0Class A Common StockSEC:0001209191-21-038687:0
21,067 shares0Class A Common StockSEC:0001209191-21-038698:0
44,150 shares0Class A Common StockSEC:0001209191-21-030634:0
25 of 81 declarations
About SOC Telemed, Inc.
SOC Telemed, Inc. (ticker TLMD) was a United States-based acute-care telemedicine company that was previously listed on the NASDAQ market. The company was acquired by Patient Square Capital in April 2022 and, following the closing of that transaction, its Class A common stock and warrants ceased trading and were delisted. For investors looking at the company’s legacy profile, this means TLMD should be viewed primarily as a former public healthcare technology name rather than an actively traded equity today.
The company was founded in 2004 under the name Specialists On Call, Inc. and built its business around providing on-demand access to physicians and specialists through telemedicine. Its operational headquarters were disclosed in Reston, Virginia, in the United States. SOC Telemed’s original and core proposition was to help hospitals extend specialist coverage, especially in time-sensitive acute-care settings where rapid clinical decision-making matters. Over time, the company positioned itself as a national provider of acute-care telemedicine, a framing that highlights both scale and specialization.
Read moreShow less
Its business model centered on hospital-focused services rather than consumer telehealth. SOC Telemed provided remote clinical consultations for emergency departments, intensive care units, and other acute-care environments. The service offering combined a physician network, clinical workflow management, and enabling technology intended to improve access, reduce delays in care, and support hospital staffing constraints. In practical terms, the company’s value proposition was to be an outsourced, digitally enabled extension of hospital specialist coverage.
A key development in the company’s expansion strategy was the March 2021 acquisition of Access Physicians, a multi-specialty acute telemedicine provider. That transaction broadened the company’s capabilities and supported its national reach. SOC Telemed’s competitive position historically rested on three pillars: a recognized specialty in acute-care telemedicine, a national operating footprint across the United States, and a platform designed for institutional health-system customers. In a competitive landscape that includes larger telehealth platforms and hospital service providers, its differentiation came from focus and clinical workflow depth rather than broad consumer brand awareness.
Recent notable events were dominated by the 2022 take-private transaction with Patient Square Capital. That deal ended TLMD’s life as a public company and is the most relevant recent milestone for market participants. From an industry perspective, SOC Telemed remains a useful case study in the structural shift toward digital care delivery, but also in the operational and financial challenges of scaling telemedicine in a hospital environment. In short, SOC Telemed is best understood as a former NASDAQ-listed United States healthcare company that specialized in hospital-based acute telemedicine.
